Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Optimer Pharmaceuticals
company
About
Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing
- 251 - 500
Details
- Last Funding Type
- Series D
- Last Funding Money Raised
- $22.20M
- Industries
- Biotechnology,Health Care,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 1998
- Number Of Employee
- 251 - 500
- Operating Status
- Close
Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. It has two late-stage anti-infective product candidates, fidaxomicin and Pruvel (prulifloxacin). Optimer's development efforts are focused on products that treat gastrointestinal infections, and related diseases where therapies have limitations. Its product portfolio includes Fidaxomicin, Pruvel, CEM-101, OPT-822/OPT-821 Combination Therapy and OPT-88.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$22.20M
Optimer Pharmaceuticals has raised a total of
$22.20M
in funding over 2 rounds. Their latest funding was raised on
Dec 14, 2005 from a Series D round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 14, 2005 | Series D | $22.20M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Optimer Pharmaceuticals is funded by 1 investors.
SB Life Science
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
SB Life Science
|
— | Series D |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
